Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
February 13 2024 - 8:00AM
Aligos Therapeutics, Inc. (Nasdaq: ALGS) (“Aligos”), a clinical
stage biopharmaceutical company focused on developing novel
therapeutics to address unmet medical needs in liver and viral
diseases, today announced the appointments of Jordyn Tarazi as Vice
President, Investor Relations and Corporate Communications and
Nikhil Aneja as Vice President, Finance, effective immediately.
“We are delighted to welcome Jordyn and Nikhil to the team,”
said Lesley Ann Calhoun, Executive Vice President, Chief Financial
Officer at Aligos. “Their experience and additional capabilities
will be valuable for the team as we progress towards meaningful
clinical data later this year. We are growing our team
strategically to aid us in the next phase of growth at Aligos.”
Jordyn brings a wealth of leadership experience across investor
relations, corporate communications, strategic planning, and
business development. She joins from ABio-X Holdings - Inc. where
she was instrumental in building a new life science incubator.
Previously, Jordyn served as the Head of Investor Relations at
CohBar, Inc., a company focused on metabolic dysfunction-associated
steatohepatitis (MASH) and other inflammatory/fibrotic indications.
She began her career in investment banking, where she assisted
companies in raising more than $1B dollars. Jordyn graduated summa
cum laude from DePaul University.
“I am thrilled to join the exceptional Aligos Team,” stated
Jordyn Tarazi, VP, Investor Relations and Corporate Communications
at Aligos. “This is an exciting time for the MASH space, and we are
well positioned to continue advancing our potential best in class
pipeline. I look forward to sharing our exciting story to our
stakeholders.”
Nikhil brings decades of finance and accounting leadership
experience. He joins from CareDx, Inc., where he led a global
accounting team and oversaw all aspects of financial reporting.
Nikhil has worked in life sciences in roles of increasing
responsibility throughout his career, including Global Blood
Therapeutics, Inc. and ZS Pharma, Inc. He graduated with Honors
from the Sri Ram College of Commerce, is a Certified Public
Accountant (CPA) and Associate Chartered Accountant, Institute of
Chartered Accountants of India (CA).
“I am excited to join Aligos at this important time in the
company’s evolution,” stated Nikhil Aneja, VP, Finance at Aligos.
“I look forward to being part of the team as we work to deliver
meaningful therapeutics to patients with liver and viral
diseases.”
About AligosAligos Therapeutics, Inc. is a
clinical stage biopharmaceutical company that was founded in 2018
with the mission to become a world leader in the treatment of liver
and viral diseases. Aligos’ strategy is to harness the deep
expertise and decades of drug development experience its team has
in liver and viral diseases to discover and develop potentially
best in class therapeutics for metabolic dysfunction-associated
steatohepatitis (MASH) and viruses with high unmet medical need
such as coronaviruses and chronic hepatitis B (CHB).
Forward-Looking Statement This press release
contains forward-looking statements within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995. Any statements in
this press release that are not historical facts may be considered
“forward-looking statements,” including without limitation,
statements with respect to the company’s progress towards
meaningful clinical data later this year; growing the team
strategically to aid in the next phase of growth at Aligos; and
being well positioned to continue advancing the company’s potential
best in class pipeline. Forward-looking statements are typically,
but not always, identified by the use of words such as “may,”
“will,” “would,” “believe,” “intend,” “plan,” “anticipate,”
“estimate,” “expect,” and other similar terminology indicating
future results. Such forward looking statements are subject to
substantial risks and uncertainties that could cause our
development programs, future results, performance, or achievements
to differ materially from those anticipated in the forward-looking
statements. Such risks and uncertainties include, without
limitation, risks and uncertainties inherent in the drug
development process, including Aligos’ clinical-stage of
development, the process of designing and conducting clinical
trials, the regulatory approval processes, the timing of regulatory
filings, the challenges associated with manufacturing drug
products, Aligos’ ability to successfully establish, protect and
defend its intellectual property, other matters that could affect
the sufficiency of Aligos’ capital resources to fund operations,
reliance on third parties for manufacturing and development
efforts, and the impact of global events and other macroeconomic
conditions on the Aligos’ business. For a further description of
the risks and uncertainties that could cause actual results to
differ from those anticipated in these forward-looking statements,
as well as risks relating to the business of Aligos in general, see
Aligos’ Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission on November 2, 2023 and its future periodic
reports to be filed or submitted with the Securities and Exchange
Commission. Except as required by law, Aligos undertakes no
obligation to update any forward-looking statements to reflect new
information, events or circumstances, or to reflect the occurrence
of unanticipated events.
Contacts
CompanyJordyn TaraziVice President, Investor
Relations & Corporate Communications(650)
910-0427jtarazi@Aligos.com
MediaVeronica Eames LifeSci Communications
veames@lifescicomms.com
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From Apr 2024 to May 2024
Aligos Therapeutics (NASDAQ:ALGS)
Historical Stock Chart
From May 2023 to May 2024